• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同一屋檐下:成瘾护理中慢性丙型肝炎的识别、评估和治疗。

Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care.

机构信息

Department of Family Medicine and Community Health, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA.

Barre Family Health Center, 151 Worcester Road, Barre, MA, 01005, USA.

出版信息

Addict Sci Clin Pract. 2018 Apr 25;13(1):10. doi: 10.1186/s13722-018-0111-7.

DOI:10.1186/s13722-018-0111-7
PMID:29690936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5937807/
Abstract

For over a decade, the vast majority of new hepatitis C virus (HCV) infections have been among young people who inject drugs (PWID). Well-characterized gaps in chronic HCV diagnosis, evaluation, and treatment have resulted in fewer than 5% of PWID receiving HCV treatment. While interferon-based treatment may have intentionally been foregone during part of this time in anticipation of improved oral therapies, the overall pattern points to deficiencies and treatment exclusions in the health care system. Treatment for HCV with all-oral, highly effective direct-acting antiviral medication for 12 weeks or less is now the standard of care, putting renewed focus on effective delivery of care. We describe here both the need for and process of chronic HCV care under the roof of addiction medicine.

摘要

十多年来,绝大多数新的丙型肝炎病毒 (HCV) 感染发生在注射毒品的年轻人 (PWID) 中。慢性 HCV 诊断、评估和治疗方面的特点明显不足,导致不到 5%的 PWID 接受 HCV 治疗。虽然在这段时间的一部分,由于预期会有更好的口服疗法,干扰素为基础的治疗可能被故意放弃,但总体情况表明医疗体系存在不足和治疗排斥。用全口服、高效直接作用抗病毒药物治疗 12 周或更短时间治疗 HCV 现在是标准的治疗方法,这重新强调了有效提供护理的重要性。我们在这里描述了成瘾医学框架下慢性 HCV 护理的必要性和流程。

相似文献

1
Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care.同一屋檐下:成瘾护理中慢性丙型肝炎的识别、评估和治疗。
Addict Sci Clin Pract. 2018 Apr 25;13(1):10. doi: 10.1186/s13722-018-0111-7.
2
The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England.《通过治疗提高丙型肝炎认识(HepCATT)研究:改善英格兰丙型肝炎病毒感染的注射吸毒者的护理衔接》。
Addiction. 2019 Jun;114(6):1113-1122. doi: 10.1111/add.14569. Epub 2019 Mar 12.
3
Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.直接作用抗病毒治疗时代既往静脉吸毒的慢性丙型肝炎患者治疗模式的改变。
J Gastroenterol Hepatol. 2019 Sep;34(9):1641-1647. doi: 10.1111/jgh.14622. Epub 2019 Feb 18.
4
'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.“全面治疗我这个人,而不仅仅是我的病情”:注射吸毒者的丙型肝炎护理提供偏好的定性探索。
Addict Sci Clin Pract. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8.
5
Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?注射毒品者慢性丙型肝炎感染的治疗与一级预防:在高流行环境中能否实现消除?
Addiction. 2017 Jul;112(7):1290-1299. doi: 10.1111/add.13764. Epub 2017 Feb 17.
6
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.静脉注射吸毒者中丙型肝炎病毒的动态变化表明,每年治疗率超过10%将在2030年前消除该疾病。
Swiss Med Wkly. 2017 Nov 8;147:w14543. doi: 10.4414/smw.2017.14543. eCollection 2017.
7
Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.估算澳大利亚注射吸毒人群中丙型肝炎的共识级联护理:直接作用抗病毒治疗的前后。
Int J Drug Policy. 2020 Sep;83:102837. doi: 10.1016/j.drugpo.2020.102837. Epub 2020 Jul 6.
8
The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.坦桑尼亚达累斯萨拉姆注射吸毒人群的丙型肝炎关怀链。
J Viral Hepat. 2018 Dec;25(12):1438-1445. doi: 10.1111/jvh.12966. Epub 2018 Jul 30.
9
Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.针对减少伤害和注射吸毒者慢性丙型肝炎治疗流程的干预措施的有效性和成本效益:以法国为例。
J Viral Hepat. 2018 Oct;25(10):1197-1207. doi: 10.1111/jvh.12919. Epub 2018 May 9.
10
Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs.评估农村地区注射吸毒人群中改良的当日检测和治疗模型的可行性。
Harm Reduct J. 2023 Apr 12;20(1):48. doi: 10.1186/s12954-023-00780-3.

引用本文的文献

1
Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.针对酒精性肝病和酒精使用障碍全谱系的综合协作式照护。
Hepatology. 2024 Dec 1;80(6):1408-1423. doi: 10.1097/HEP.0000000000000996. Epub 2024 Jun 27.
2
Association of psychosocial risk factors and liver transplant evaluation outcomes in metabolic dysfunction-associated steatotic liver disease.代谢相关脂肪性肝病患者的心理社会风险因素与肝移植评估结果的相关性。
Liver Transpl. 2024 Dec 1;30(12):1226-1237. doi: 10.1097/LVT.0000000000000421. Epub 2024 Jun 12.
3
Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic.在一家私人诊所,丙型肝炎综合治疗与改善阿片类药物使用障碍门诊治疗的留存率及成功率相关。
Front Psychiatry. 2022 Sep 14;13:932306. doi: 10.3389/fpsyt.2022.932306. eCollection 2022.
4
Hepatitis C models of care: approaches to elimination.丙型肝炎护理模式:消除丙型肝炎的方法。
Can Liver J. 2020 Jun 4;3(2):165-176. doi: 10.3138/canlivj.2019-0002. eCollection 2020 Spring.
5
Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting.多学科成瘾治疗项目中直接作用抗病毒药物治愈的丙型肝炎感染患者的初级保健与随访病毒载量检测相关:真实世界环境中的观察结果。
J Addict Med. 2022;16(3):333-339. doi: 10.1097/ADM.0000000000000910.
6
Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders.物质使用障碍患者丙型肝炎病毒治疗的级联反应。
Am J Prev Med. 2021 Oct;61(4):576-584. doi: 10.1016/j.amepre.2021.04.013. Epub 2021 Jun 29.
7
Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug-Drug Interactions with Antiviral Treatments for Hepatitis C.阿片类物质使用障碍患者的药物治疗概况:丙型肝炎抗病毒治疗相关药物相互作用的考量
Pathogens. 2021 May 24;10(6):648. doi: 10.3390/pathogens10060648.
8
Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City.纽约市注射吸毒者的注射器服务项目提供丙型肝炎护理的可接受性和有效性。
Subst Use Misuse. 2021;56(5):728-737. doi: 10.1080/10826084.2021.1892142. Epub 2021 Mar 7.
9
The opioid epidemic: Mobilizing an academic health center to improve outcomes.阿片类药物流行:动员学术医疗中心改善结果。
J Subst Abuse Treat. 2021 Feb;121:108199. doi: 10.1016/j.jsat.2020.108199. Epub 2020 Nov 13.
10
Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.在阿片类药物治疗项目中患者的丙型肝炎病毒(HCV)护理连续性结局和 HCV 社区病毒载量。
J Infect Dis. 2020 Sep 2;222(Suppl 5):S335-S345. doi: 10.1093/infdis/jiz686.

本文引用的文献

1
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2019年丙型肝炎指南更新:美国肝病研究协会-美国传染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
2
Hepatitis Awareness Month and Testing Day - May 2019.肝炎宣传月和检测日-2019 年 5 月。
MMWR Morb Mortal Wkly Rep. 2019 May 10;68(18):413. doi: 10.15585/mmwr.mm6818a1.
3
Hepatitis C in injection drug users: It is time to treat.注射吸毒者中的丙型肝炎:是时候治疗了。
World J Gastroenterol. 2017 May 28;23(20):3569-3571. doi: 10.3748/wjg.v23.i20.3569.
4
Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach.识别和表征马萨诸塞州丙型肝炎病毒热点地区:一种空间流行病学方法。
BMC Infect Dis. 2017 Apr 20;17(1):294. doi: 10.1186/s12879-017-2400-2.
5
A Public Health Approach to Hepatitis C in an Urban Setting.城市环境中丙型肝炎的公共卫生应对方法。
Am J Public Health. 2017 Jun;107(6):922-926. doi: 10.2105/AJPH.2017.303718. Epub 2017 Apr 20.
6
Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program.在阿片类药物治疗项目中使用直接作用抗病毒药物对丙型肝炎病毒感染进行现场治疗。
J Subst Abuse Treat. 2017 Apr;75:49-53. doi: 10.1016/j.jsat.2016.12.014. Epub 2017 Jan 24.
7
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.在低门槛药物治疗机构采用不含干扰素的全口服方案对慢性丙型肝炎进行直接观察治疗——针对接受阿片类药物替代治疗且依从性存疑患者的一种新治疗理念。
Am J Gastroenterol. 2016 Jun;111(6):903-5. doi: 10.1038/ajg.2016.119.
8
Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.在基于办公室的阿片类药物使用障碍项目中接受丁丙诺啡治疗的人群中进行丙型肝炎病毒检测与治疗
J Subst Abuse Treat. 2016 Jul;66:54-9. doi: 10.1016/j.jsat.2016.01.009. Epub 2016 Feb 13.
9
Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: A retrospective cohort study.接受阿片类药物维持治疗的孕妇丙型肝炎病毒感染的筛查与评估:一项回顾性队列研究。
Subst Abus. 2016;37(1):88-95. doi: 10.1080/08897077.2015.1118720. Epub 2015 Nov 16.
10
The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.美国慢性丙型肝炎病毒感染的治疗流程:一项系统评价与荟萃分析
PLoS One. 2014 Jul 2;9(7):e101554. doi: 10.1371/journal.pone.0101554. eCollection 2014.